^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    FPI-1434

    i
    Other names: FPI-1434, [225Ac]-FPI-1434 Injection, FPX01
    Associations

    News

    Trials
    Company:
    Fusion Pharma
    Drug class:
    IGF-1R inhibitor, α radiation emission
    Related drugs:
    Associations

    News

    Trials
    8ms
    A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1/2, N=253, Recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jun 2023 --> Jun 2024
    Trial primary completion date • Metastases
    |
    IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    HER-2 negative
    |
    FPI-1434
    over1year
    Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227. (PubMed, Front Med (Lausanne))
    This review will detail experience using the alpha emitter radium-223 (Ra, tradename Xofigo), that targets bone formation, in osteosarcoma, specifically related to patient selection, use of gemcitabine for radio-sensitization, and using denosumab to increasing the osteoblastic phenotype of these cancers. A case of an inoperable left upper lobe vertebral-paraspinal-mediastinal osteoblastic lesion treated successfully with Ra combined with gemcitabine is described. Because not all areas of osteosarcoma lesions are osteoblastic, but nearly all osteosarcoma cells overexpress IGF1R, and some subsets expressing Her-2, the anti-IGF1R antibody FPI-1434 linked to actinium-225 (Ac) or the Her-2 antibody linked to thorium-227 (Th) may become other means to provide targeted alpha particle therapy against osteosarcoma (NCT03746431 and NCT04147819).
    Review • Journal
    |
    IGF1R (Insulin-like growth factor 1 receptor)
    |
    HER-2 expression • IGF1R expression • IGF1R overexpression
    |
    gemcitabine • Prolia (denosumab) • Xofigo (radium Ra-223 dichloride) • FPI-1434
    over1year
    A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1/2, N=227, Recruiting, Fusion Pharmaceuticals Inc. | Trial primary completion date: Jun 2022 --> Jun 2023
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    HER-2 negative
    |
    FPI-1434
    over2years
    A Phase 1/2 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1/2, N=227, Recruiting, Fusion Pharmaceuticals Inc. | Phase classification: P1 --> P1/2 | N=38 --> 227 | Trial completion date: Dec 2022 --> Jun 2026
    Phase classification • Enrollment change • Trial completion date
    |
    IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    FPI-1434
    over3years
    A Phase 1 Study of [225Ac]-FPI-1434 Injection (clinicaltrials.gov)
    P1, N=38, Recruiting, Fusion Pharmaceuticals Inc. | Trial completion date: Jan 2021 --> Dec 2022 | Trial primary completion date: Jul 2020 --> Apr 2022
    Clinical • Trial completion date • Trial primary completion date
    |
    IGF1 (Insulin-like growth factor 1) • IGFBP3 (Insulin-like growth factor binding protein 3)
    |
    FPI-1434